Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · IEX Real-Time Price · USD
1.340
+0.010 (0.75%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Akebia Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Akebia Therapeutics stock have an average target of 4.67, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 248.51% from the current stock price of 1.34.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2024.
Analyst Ratings
The average analyst rating for AKBA stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $6 | Strong Buy | Maintains | $5 → $6 | +347.76% | Mar 28, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +273.13% | Mar 15, 2024 |
BTIG | BTIG | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +198.51% | Nov 29, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3.75 → $5 | Strong Buy | Maintains | $3.75 → $5 | +273.13% | Nov 17, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3.75 | Strong Buy | Reiterates | $3.75 | +179.85% | Sep 27, 2023 |
Financial Forecast
Revenue This Year
192.87M
from 194.62M
Decreased by -0.90%
Revenue Next Year
174.92M
from 192.87M
Decreased by -9.31%
EPS This Year
-0.30
from -0.28
EPS Next Year
-0.29
from -0.30
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 200.6M | 208.5M | 252.9M | 404.7M | 629.8M |
Avg | 192.9M | 174.9M | 242.2M | 327.3M | 441.8M |
Low | 184.3M | 123.4M | 229.3M | 251.3M | 261.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 3.1% | 8.1% | 44.6% | 67.1% | 92.4% |
Avg | -0.9% | -9.3% | 38.4% | 35.2% | 35.0% |
Low | -5.3% | -36.0% | 31.1% | 3.8% | -20.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -0.22 | 0.18 | 0.43 | 0.62 | 1.70 |
Avg | -0.30 | -0.29 | 0.15 | 0.59 | 1.16 |
Low | -0.36 | -0.57 | -0.12 | 0.55 | 0.65 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | 318.9% | 190.0% |
Avg | - | - | - | 296.6% | 98.3% |
Low | - | - | - | 271.1% | 10.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.